1. Home
  2. KXIN vs SHPH Comparison

KXIN vs SHPH Comparison

Compare KXIN & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$4.45

Market Cap

9.3M

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$3.60

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
SHPH
Founded
2015
2012
Country
China
United States
Employees
13
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
5.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
KXIN
SHPH
Price
$4.45
$3.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
55.6K
300.4K
Earning Date
11-26-2019
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.38
52 Week High
$22.00
$5.59

Technical Indicators

Market Signals
Indicator
KXIN
SHPH
Relative Strength Index (RSI) 35.45 69.57
Support Level $4.21 $3.41
Resistance Level $5.86 $3.56
Average True Range (ATR) 0.47 0.34
MACD -0.15 0.29
Stochastic Oscillator 7.04 71.70

Price Performance

Historical Comparison
KXIN
SHPH

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: